Goldline Pharmaceutical's ₹11.61 crore IPO allotment status is expected to be finalised today, May 15, 2026. Investors can verify their allotment details via the official websites of BSE and the issue's registrar, Bigshare Services Private Limited.
Procedure to Check Goldline Pharmaceutical IPO Allotment Status Online On BSE
- Clickhere to visit the application status page.
- In Issue Type, 'Equity'.
- In Issue Name, select 'Goldline Pharmaceutical Limited '
- Enter your 'Application No. or PAN No.'
- Enter the given Captcha correctly.
- Click 'Submit'.
Procedure to Check Goldline Pharmaceutical IPO Allotment Status on Bigshare Services (Registrar to the issue)
- Visit the Bigshare Services' IPO allotment status page here.
- Click on any one of the three servers available on the page.
- In Select Company, select 'Goldline Pharmaceutical Ltd'.
- Enter any of the following details.
- Application No./CAF No
- Beneficiary ID
- PAN Number
- Enter the captcha and click 'Search'.
Goldline Pharmaceutical IPO - Issue Details
Issue Type: Book Building IPO
Total Issue size: 27 lakh equity shares
Fresh Issue: 27 lakh equity shares
Price Band: ₹41 to ₹43 per share
Face Value: ₹10 each
Lot Size: 3,000 shares
Minimum Investment: ₹2,58,000 (6,000 shares)
Book Running Lead Managers: Cumulative Capital Private Limited
Registrar: Bigshare Services Private Limited
Listing: BSE SME
Goldline Pharmaceutical IPO Overall Subscription Status
[May 14, 2026, 07:00 PM]
Category | Subscription (Times) |
Qualified Institutional Buyers (QIBs) | 11.52 |
Non-Institutional Investors (NIIs) | 365.75 |
Retail Investors | 264.47 |
Total | 211.41 |
Goldline Pharmaceutical IPO GMP
According to media reports, theGrey Market Premium (GMP) of Goldline Pharmaceutical's unlisted shares is ₹15 per share today.
Utilisation of IPO Proceeds
The Company will utilise the net proceeds from the Fresh Issue towards the following purposes:
- Repayment of all or a portion of certain outstanding borrowings availed by the company
- General Corporate Purposes.
Check out newlylisted IPOs on BSE and NSE.
Goldline Pharmaceutical Limited Overview
Established in 2004, Goldline Pharmaceuticals Limited specialises in pharmaceutical marketing across five primary segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness.
To ensure a reliable supply chain and a steady market presence, the company currently collaborates with 15 manufacturers and 8 distributors under contractual agreements.
As of the period ending December 31, 2025, the company achieved an operational revenue of ₹21.40 crore. During the same period, Profit after Tax (PAT) was ₹2.22 crore, with EBITDA of ₹4.15 crore.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please clickhere.